A complex for serving diabetics to reduce the concentration of blood glucose is provided, including a transferrin and a metal ion (or an oxidized metal ion). The transferrin can carry the metal ion (or the oxidized metal ion) into cells of a patient, thereby encouraging glucose uptake by the cells and reducing the toxicity of the metal ion (or the oxidized metal ion). Furthermore, the complex has the capability of reducing insulin resistance, and therefore is available to treat high blood glucose in type 2 diabetes and reduce insulin resistance. A process for reducing blood glucose of a diabetic patient includes providing a composition comprised of a complex of transferrin and at least one metal ion. A dose of the composition is administered to the diabetic patient in an amount effective to encourage glucose uptake by the cells and reduction of glucose in the blood as the transferrin carries the metal ion (or the oxidized metal ion) into the cells of the diabetic patient.